Abstract KRO-105714, N-(5-benzoyl-2-(4-(2-methoxyphenyl) piperazin-1-yl)thiazol-4-yl)pivalamide, is a 2,4,5-trisubstituted 1,3-thiazole derivative that exerts anti-atopic dermatitis activity via robust suppression of the sphingosylphosphorylcholine receptor. This study used highresolution/high-accuracy tandem mass spectroscopy (HRMS) and recombinant complementary DNA (cDNA)-expressed cytochrome P450 isoforms (P450) to identify the metabolic pathway and metabolites of KRO-105714 in human liver microsomes (HLMs) as therapeutic agents for inflammation. The incubation of KRO-105714 with pooled HLMs in the presence of nicotinamide adenine dinucleotide phosphate generated four metabolites (M1-M4). The metabolites were identified using HRMS and confirmed using synthetic standards for M2 and M4. M1 and M2 were identified as mono-hydroxylated metabolites, and M3 and M4 were further identified as O-demethyl and C-demethyl- KRO-105714, respectively. In the inhibition study with selective CYP3A4 inhibitors and incubation in recombinant cDNA-expressed CYPs, all the metabolites of KRO-105714 were formed by CYP3A4 in HLMs. The CYP3A4-mediated formation of M4 from M2 was confirmed via incubation of M2 in HLMs. These results showed that the unusual C-demethylated metabolite M4 was generated from mono-hydroxyl metabolite M2 via a CYP3A4-mediated enzymatic reaction in HLMs.
Introduction
Sphingosylphosphorylcholine (SPC) is structurally similar to sphingosine-1-phosphate, which along with lysophosphatidic acid (LPA) is classified as a lysophospholipid. These substances are act as important signaling intermediates in the cell proliferation, migration, and inflammatory responses of immune function (Nixon et al., 2008) . SPC is generated by the action of sphingomyelindeacylase from sphingomyelin, a structural component of cell membranes (Higuchi et al., 2000; Nixon et al., 2008) . Furthermore, SPC displays a wide range of biological activities such as angiogenesis, activation of calcium signaling, protection of cells from apoptosis, and stimulation of nitric oxide production (Desai and Spiegel, 1991; Chen et al., 1998; Boguslawski et al., 2000; Higuchi et al., 2000; Jeon et al., 2005) . Atopic dermatitis is an example of an SPC-related disease (Imokawa, 2009) . Patients with the disease experience pain, itching, and poor quality of life. Direct intradermal injection of SPC has shown that SPC causes itching owing to its structural similarity to LPA (Hashimoto et al., 2004) . KRO-105714, N-(5-benzoyl-2-(4-(2-methoxyphenyl) piperazin-1-yl)thiazol-4-yl)pivalamide, is a 2,4,5-trisubstituted 1,3-thiazole derivative and therapeutic agent for antiinflammatory diseases induced by SPC (Gong et al., 2009) . The SPC receptor is inhibited by these novel derivatives, and the anti-inflammatory effect of KRO-105714 has been confirmed using dermal cells derived from humans and mice. As a part of the preclinical study of KRO-
A number of analytical techniques have been developed for detection and determination in drug metabolism studies. For example, HRMS techniques such as quadrupole time-of-flight, Fourier transform ion cyclotron resonance mass spectrometry (MS), and hybrid highresolution tandem mass spectrometry (MS/MS; Orbitrap) have been applied to identify metabolite structure. Orbitrap, the newest addition to the HRMS family (Zubarev and Makarov, 2013) , is based on high resolution in excess of 1,000,000 full width at half maximum. In investigations of drug metabolites, accurate measurement using HRMS is beneficial in that the change in elemental compositions is performed with accurate masses and charge states below 5 ppm (Lee et al., 2013) .
In the present study, KRO-105714 was metabolized to four metabolites including Cdemethyl, O-demethyl, and two mono-hydroxyl KRO-105714s. Among these reactions, Cdemethyl KRO-105714 is an uncommon product of metabolic enzymatic reactions; therefore, and the other chemicals were of the highest quality available.
Biotransformation of KRO-105714
KRO-105714 (50 μM final concentration) was incubated with 1 mg/mL pooled HLMs at 37°C for 90 min in the presence of an NADPH-generating system (NGS) containing 0.1 M glucose 6-phosphate, 10 mg/ml β -NADPH, and 1.0 unit/mL β -glucose 6-phosphate dehydrogenase at a final volume of 100 μl. The reaction was stopped via addition of 1 ml of ethyl acetate, and after mixing for 1 min, the samples were centrifuged at 13,000 rpm for 5 min at 20°C. Then, 900 μl of supernatant was separated and removed via evaporation. The samples were reconstituted with 100 μl of acetonitrile in 0.1% formic acid and centrifuged at 13,000 rpm for 10 min at 20°C. The supernatants were diluted with 400-μl LC-grade water and injected into an HPLC column for linear trap quadrupole Orbitrap analysis.
Chemical inhibition studies and metabolism with cDNA-expressed CYP isoforms
The inhibitory effects of known CYP isoform-selective inhibitors and the metabolism of KRO-105714 were evaluated to determine the CYP isoforms involved in the metabolic pathway. Well-characterized CYP-selective inhibitors -i.e., α-naphthoflavone for CYP1A2 (1 and 5 μM), tranylcypromine for CYP2A6 (1 and 5 μM), quercetin for CYP2C8 (5 and 20 μM), fluconazole for CYP2C9 (5 and 10 μM), ticlopidine for CYP2C19 (2 and 10 μM), quinidine for CYP2D6 (10 and 50 μM), diethyldithiocarbamate for CYP2E1 (20 and 100 μM), and ketoconazole for CYP3A4 (2 and 10 μM) -were incubated with KRO-105714(Newton et al., 1995; Ko et al., 2000; Lee et al., 2008; Khojasteh et al., 2011) .
Incubations were performed with CYP-selective inhibitor pooled HLMs (1 mg/ml) and KR-105714 (50 μM). The activity of all the inhibitors was compared with that of inhibitor-free controls.
The incubation mixtures, including 5 μl of recombinant cDNA-expressed CYP (diluted to 10 pmol/mL with phosphate buffer, pH 7.4) and KRO-105714 (50 μM) reconstituted in 0.1 M phosphate buffer (pH 7.4), were pre-incubated for 5 min at 37°C. The reaction was started by adding the NGS, and the reaction mixtures (final volumes of 100 μ l) were incubated for 60 min at 37°C in a thermo shaker. The reaction was stopped by adding 500-μl ethyl acetate after mixing and centrifuged at 13,000 rpm for 10 min at 20°C. In all experiments, KRO-105714 was dissolved in ethyl acetate; the solvent was subsequently removed via evaporation to dryness under reduced pressure. The residues were reconstituted with 100 μl of 50% acetonitrile (in formic acid 0.1%), and then the internal standard solution (reserpine, 3.0 ng/mL; 5 μ l) was added. The supernatants were transferred to auto-sampler vials, and 10-μl The mobile phases consisted of 0.1% formic acid in acetonitrile (A) and 0.1% formic acid in LC-grade water (B). Gradient elution was conducted as follows: B was linearly increased from 30% to 95% for 7 min, retained at 95% for an additional 5 min, and then directly decreased to 30% and held at 30% for equilibration for 5 min at a flow rate of 200 μl/min. 
Characterization of metabolites in HLMs
Metabolite structures were characterized and assigned based on their HRMS, MS 2 , and MS Figure   3A ). The protonated ion at m/z 246.07007 (C 12 H 12 O 1 N 3 S 1 ) was generated after cleavage of a cyclohexane (see Figure 3A ). Metabolite M2, the major metabolite peak, gave an spectrum pattern identifying M2 fragmentation is the same as that of M4 ( Figure 3D ).
Therefore, M4 was proposed as a C-demethylated metabolite with an alkoxy group moiety.
Identification of M2 and M4 metabolism
Metabolites M2 and M4 were further confirmed through comparison with synthetic standards (Supplemental Figure 1) . These synthetic standards showed the same MS 2 and MS 3 patterns as those of M2 and M4 (Figure 3 and Supplemental Figure 2 ). Co-elution with authentic metabolites using the same LC conditions revealed matching mass peaks and retention times with synthetic standards (Figure 4 ). After simultaneous analysis of metabolites and synthetic standards, the structures of metabolites M2 and M4 were confirmed to result from monohydroxylation and C-demethylation, respectively, of an alkoxy group.
We then hypothesized that C-demethylation metabolite M4 could be generated from the C-hydroxylation of metabolite M2 via removal of methanol in the alkoxy group. To confirm this hypothesis, we incubated M2 in HLMs and characterized the generated metabolites. M4
was collected using equivalent LC-MS/MS conditions, and the postulated metabolic pathway
showing that M4 generated from M2 was confirmed (Supplemental Figure 3) . Moreover, 
Identification of major CYP isoforms involved in C-demethylation of KRO-10714
The CYP isozymes responsible for the oxidative metabolism of KRO-105714 were identified using both selective inhibitors of CYP enzymes and incubation with human recombinant cDNA-expressed CYPs. The effects of selective inhibitors of CYP enzymes on KRO-105714 metabolism in HLMs are shown in Table 3 
Discussion
The metabolic disposition of KRO-105714 in HLMs had not been researched previously. In this study, we attempted to determine the postulated metabolites, metabolic enzymes, and metabolic pathway of KRO-105714 in HLMs. KRO-105714 is primarily metabolized to mono-hydroxylation (M1), C-hydroxylation (M2), demethylation (M3), and C-demethylation (M4) metabolites in HLMs (Figure 6 ). In particular, the structure of M4 was partly unexpected, as C-demethylation is uncommon during drug metabolism, whereas O-and Ndemethylations are frequently observed in the biotransformation of xenobiotics (Burke et al., 1994; Coutts et al., 1994; Ertl et al., 1999) .
To confirm the unusual C-demethylation of KRO-105714, we analyzed the elemental composition of generated metabolites using Orbitrap MS. A loss of 14.01534 Da in M4 compared to the composition of KRO-105714 indicated that the former is a demethylated metabolite, and MS 2 and MS 3 analyses using HRMS confirmed the C-methylation of KRO-105714. In addition, we prepared synthetic C-demethylated KRO-105714 as a gold standard, and the structure of M4 was confirmed through comparison of MS 2 and MS 3 fragmentation and chromatographic co-elution. Moreover, the generation mechanism of C-demethylation in
Aplidine, a potent marine-derived anti-cancer drug, is C-demethylated at the (R)-N(methyl)-leucine group by CYP2A6 in pooled HLMs (Brandon et al., 2007) . In the present study, CYP-reaction-enzyme phenotyping strongly suggested that KRO-105714 is primarily metabolized by mono-hydroxylation and C-demethylation at the alkoxy group moiety by CYP3A4 in HLMs. In short, the most dominant CYP3A4 in HLMs might contribute to the unusual drug metabolism depending on the partial structure of the target.
In conclusion, we demonstrated that KRO-105714 is metabolized to two mono-hydroxyl KRO-105714, N-(5-benzoyl-2-(4-(2-methoxyphenyl) KRO-105714, N-(5-benzoyl-2-(4-(2-methoxyphenyl) 
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